

Supplemental Table 1. Baseline characteristics of University Arizona Cancer Center Gastrointestinal cancer patients retrospective review compared to AMPLIFY<sup>[27]</sup>, pooled-EINSTEIN<sup>[28]</sup>, and Hokusai<sup>[29]</sup>, extracted Gastrointestinal cancer subgroup analysis.

Baseline Characteristics	<i>Enoxaparin</i> (UACC)	Hokusai (Dalteperin)	<i>Apixaba</i> <i>n</i> (UACC)	AMPLIFY (Apixaban)	<i>Rivaroxaban</i> (UACC)	EINSTEIN (Rivaroxaban)
N (%)	40	140	29	81	37	71
Age at VTE event (years)	66±10.1	63.7±11.7	67.5±10.9	65.5±16	65±10.6	57.9±7.3
Weight mean (%)	72.1±19.1	79.1±8.1				
<50Kg			7.1	8.6	0	2.1
50-100kg			82.1	71.8	91.2	83
>100kg			10.8	19.4	8.8	14.9
Gender (Male %)	45	50	59	57	65	59
Creatinine clearance <50mL/min (%)	7.5	6.5	7.1	8	11.7	13
Antiplatelet therapy	12.50%	Excluded	5 (17%)	Excluded	3 (8%)	Excluded
Prior treated VTE (%)	5	12	7	17.2	13	18.8
GI Cancer Location						
Upper GI (Including HPB)	25 (62.5%)	61 (11.6%)	18 (64.2%)	NA	19 (51.4%)	29 (40.8%)
Lower GI	15 (37.5%)	79 (15.1)	11 (37.9%)	10 (12.5%)	38 (48.6%)	42 (59.1%)
Recurrent or Metastatic (%)	72.5	53.4	75	30	65	19
Current Chemotherapy (%)	40	73.1	62	NA	35	35
VTE Diagnosis (%)						

PE/DVT	27.5	62.8	17	9.4	8	14
PE	17.5	NA	7	25.2	16	34.4
DVT	55	37.2	75	65	76	51
Therapy Completion 6 months (%)	62.5	54.4	69	80	65	62
Anticoagulation Length (days)	124 (31-1023)	184 (85-341)	324 (60-870)	168 (90-180)	319 (31-1290)	180 (59-186)

---

Abbreviations: University of Arizona Cancer Center (UACC), gastrointestinal (GI), Hepato-pancreato-biliary (HPB) Venous thromboembolism (VTE), pulmonary embolism (PE), deep vein thrombosis (DVT), Not available (NA).